Boehringer Ingelheim today announced that it had discontinued a phase 2 trial of its anticoagulant drug dabigatran (Pradaxa) in patients with mechanical heart valves. As reported here in October, the company had previously terminated one arm of the study after an interim review of the data by the trial’s Data Safety Monitoring Board The RE-ALIGN trial was an open-label,…
Boehringer Ends Phase 2 Trial Of Dabigatran In Mechanical Valve Patients
December 12, 2012 by 2 Comments
Recent Comments